Alex­ion pays $930M to buy out Achillion and its promis­ing com­pan­ion drug to Soliris

Af­ter a se­ries of stock-crunch­ing set­backs over the years, Achillion en­joyed a turn in the sun a few weeks ago as the FDA blessed their lead drug dan­i­co­pan (ACH-4471) — a com­ple­men­tary ther­a­py for PNH pa­tients tak­ing Alex­ion’s Soliris — with a break­through drug des­ig­na­tion af­ter tak­ing a look at some sol­id sup­port­ing Phase II da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER